Results 131 to 140 of about 5,702,542 (372)

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

Hematological Oncology, Volume 40, Issue 5, Page 987-998, December 2022., 2022
Abstract The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head comparisons are lacking.
Cirino Botta, Emilia Gigliotta, Bruno Paiva, Rita Anselmo, Marco Santoro, Paula Rodriguez Otero, Melania Carlisi, Concetta Conticello, Alessandra Romano, Antonio Giovanni Solimando, Claudio Cerchione, Matteo Da Vià, Niccolò Bolli, Pierpaolo Correale, Francesco Di Raimondo, Massimo Gentile, Jesus San Miguel, Sergio Siragusa   +17 more
wiley   +1 more source

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Science Translational Medicine, 2019
GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts. CARs to drive away multiple myeloma Chimeric antigen receptor (CAR) T cells, a type of cell-based immunotherapy, have ...
Eric L. Smith, Kimberly H. Harrington, M. Staehr, Reed Masakayan, Jon C Jones, T. Long, Khong Y. Ng, M. Ghoddusi, Terence J. Purdon, Xiuyan Wang, Trevor Do, M. Pham, Jessica M. Brown, C. F. de Larrea, E. Olson, Elizabeth Peguero, Pei Wang, Hong Liu, Yiyang Xu, Sarah C. Garrett-Thomson, S. Almo, H. Wendel, I. Rivière, Cheng Liu, Blythe Sather, R. Brentjens   +25 more
semanticscholar   +1 more source

COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular Carcinoma

Advanced Science, EarlyView.
COPS5, which is overexpressed in HCC in an amplification‐ and ATF4‐dependent manner, stabilizes MK2 through deubiquitination and, in turn, induces HSPB1 activation, protecting HCC cells from ferroptosis and thus promoting sorafenib resistance and tumor progression. Abstract Sorafenib, which is proven to serve as a potent ferroptosis inducer, is used as
Ai‐Ling Luo, Wen‐Ying Zheng, Qiong Zhang, Yan Yuan, Mei‐Qi Li, Kai Du, An‐Ran Gao, Li‐Jun Pei, Jie Xie, Wen‐Hao Chen, Long Zhang, Xiu‐Zhu Guo, Xiao‐Ran Yang, Chao Zeng, Guo‐Hua Yang, Min Deng   +15 more
wiley   +1 more source

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells

Hematological Oncology, Volume 40, Issue 5, Page 999-1008, December 2022., 2022
Abstract Mechanisms underlying interactions between a novel, clinically relevant circularized tumor necrosis factor‐related apoptosis inducing ligand (TRAIL) agonist, circularly permuted TRAIL (CPT) have been examined in multiple myeloma (MM) cells sensitive or resistant to bortezomib (BTZ).
Yun Leng, Xiaoyan Hu, Lin Li, Jewel Nkwocha, Toshihisa Satta, Kanika Sharma, Maciej Kmeiciak, Huixing Zhou, Zhiyao Zhang, Liang Zhou, Wenming Chen, Steven Grant   +11 more
wiley   +1 more source

Multiple Myeloma [PDF]

ASH Image Bank, 2001
D, Samson, C, Singer
openaire   +3 more sources

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

OncoImmunology, 2018
Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38 antibody, has been approved by the U.S. Food and Drug Administration for the treatment of relapsed multiple myeloma (MM) as a single agent as well as in combination with ...
Jayeeta Ghose, Domenico Viola, Cesar Terrazas, Enrico Caserta, Estelle Troadec, Jihane Khalife, Emine Gulsen Gunes, James Sanchez, Tinisha McDonald, Guido Marcucci, Balveen Kaur, Michael Rosenzweig, Jonathan Keats, Steven Rosen, Amrita Krishnan, Abhay R Satoskar, Craig C Hofmeister, Flavia Pichiorri   +17 more
doaj   +1 more source

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

New England Journal of Medicine, 2015
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or ...
S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Spicka, A. Walter‐Croneck, P. Moreau, M. Mateos, H. Magen, A. Belch, D. Reece, M. Beksaç, A. Spencer, H. Oakervee, R. Orlowski, M. Taniwaki, C. Röllig, H. Einsele, K. Wu, A. Singhal, J. San-Miguel, M. Matsumoto, J. Katz, E. Bleickardt, V. Poulart, K. Anderson, P. Richardson   +27 more
semanticscholar   +1 more source

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

Advanced Science, EarlyView.
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde   +3 more
wiley   +1 more source

The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study

Hematological Oncology, Volume 40, Issue 5, Page 962-975, December 2022., 2022
Abstract Chronic lymphocytic leukemia (CLL) is a hematological disorder with complex clinical and biological behavior. TP53 mutational status and cytogenetic assessment of the deletion of the corresponding locus (17p13.1) are considered the most relevant biomarkers associated with pharmaco‐predictive response, chemo‐refractoriness, and worse prognosis ...
Giuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, Romana Conte, Adalberto Ibatici, Nikki Di Felice, Fortunato Morabito, Paola Monti, Gilberto Fronza, Serena Matis, Monica Colombo, Sonia Fabris, Alessia Ciarrocchi, Antonino Neri, Paola Menichini, Manlio Ferrarini, Paolo Nozza, Franco Fais, Giovanna Cutrona, Mariella Dono   +19 more
wiley   +1 more source

A New Conceptual Framework for the Therapy by Optimized Multidimensional Pulses of Therapeutic Activity. The case of Multiple Myeloma Model [PDF]

arXiv, 2017
We developed simulation methodology to assess eventual therapeutic efficiency of exogenous multiparametric changes in a four-component cellular system described by the system of ordinary differential equations. The method is numerically implemented to simulate the temporal behavior of a cellular system of multiple myeloma cells.
arxiv